• Rakovina Therapeutics will present preclinical kt-5000AI cancer drug data November 13, 2026, at the Society for Neuro-Oncology annual meeting in Philadelphia.
• Optimized compounds showed potent, selective ATR inhibition, improved metabolic stability and properties associated with brain penetration; studies assessing central nervous system exposure continue.
• The program shifted from dual ATR-mTOR inhibition to ATR-selective compounds targeting PTEN-deficient tumors, including gliomas and cancers that spread to the brain.
• Developed using Variational AI’s Enki platform, the program reached advanced lead optimization in approximately two years.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Rakovina Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611050530PRIMZONEFULLFEED9870953) on November 05, 2026, and is solely responsible for the information contained therein.